# 2025年11月13日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. Cenobamate长期治疗对合并使用抗癫痫药物的影响：一项西班牙真实世界回顾性研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41222492](https://pubmed.ncbi.nlm.nih.gov/41222492)
**期刊：** Epilepsia
**PMID：** 41222492
**DOI：** 10.1111/epi.70006

### 第一部分 原文与翻译

**英文原标题：** Impact of long-term treatment with cenobamate on concomitant usage of antiseizure medications: A real-world retrospective study in Spain.

**英文摘要原文：**
OBJECTIVES: This study explored the safety and effectiveness of adjunctive cenobamate (CNB) in patients with different levels of drug-resistant epilepsy (DRE) in a real-world setting, including its impact on the use of co-antiseizure medication (co-ASM).

METHODS: This was a single-center, retrospective, observational study. Adults with refractory seizures who had received ≥2 previous ASMs and had been treated with CNB for at least a year were included. Effectiveness and safety endpoints were assessed at 3, 6, 12, and 24 months after CNB was initiated. Co-ASM use was assessed at every visit.

RESULTS: Ninety-four patients were included; 23 of 94 (24.5%) had received ≤4 previous ASMs and 70 of 94 (74.5%) had received ≥5 previous ASMs. Patients with ≥5 previous ASMs had a younger age at onset (mean 12 vs 25.9 years) and a longer duration of epilepsy (mean 28.1 vs 16.7 years) compared with patients with ≤4 previous ASMs. The mean CNB daily dose was 310 ± 76.7 mg at 2 years. The mean number of co-ASMs received by patients was reduced significantly between baseline and all time points (p ≤ .01). The mean defined daily dose (DDD) per patient (not including CNB) was also reduced significantly across all time points (p < .01), falling from 3.2 ± 2.3 at baseline to 1.2 ± 1.9 at the 2-year follow-up. At 1 and 2 years after initiation of CNB, 79.6% and 80% of patients had a ≥50% reduction in seizure frequency and 36.6% and 30.9% were seizure-free, respectively. At 2 years, 73.2% of patients reported their condition to be "Very much better" or "Much better" compared with baseline; 37.5% reported treatment-related adverse drug reactions at 2 years.

SIGNIFICANCE: In patients with DRE, CNB treatment allowed long-term high seizure-freedom rates and significant reductions in co-ASM use, while also achieving both good tolerability and high patient satisfaction scores.

**中文摘要译文：**
目的：本研究旨在真实世界环境下，探讨辅助性司妥赛（Cenobamate, CNB）在不同程度的药物抵抗性癫痫（DRE）患者中的安全性与有效性，包括其对合并使用的抗癫痫药物（co-ASM）的影响。

方法：这是一项单中心、回顾性、观察性研究。研究纳入了既往接受过≥2种抗癫痫药物治疗、且接受司妥赛治疗至少一年的难治性癫痫成人患者。在司妥赛起始治疗后的第3、6、12及24个月，对有效性和安全性终点进行了评估。每次随访时均对合并使用的抗癫痫药物情况进行评估。

结果：共纳入94例患者；其中23例（24.5%）既往接受过≤4种抗癫痫药物，70例（74.5%）接受过≥5种。与接受过≤4种既往抗癫痫药物的患者相比，接受过≥5种的患者起病年龄更小（平均12岁 vs 25.9岁），癫痫病程更长（平均28.1年 vs 16.7年）。治疗2年时，司妥赛的平均每日剂量为310 ± 76.7毫克。与基线相比，患者合并使用的抗癫痫药物平均数量在所有时间点均显著减少（p ≤ .01）。每位患者的平均限定日剂量（DDD）（不含司妥赛）在所有时间点也显著降低（p < .01），从基线的3.2 ± 2.3降至2年随访时的1.2 ± 1.9。在司妥赛起始治疗1年和2年后，分别有79.6%和80%的患者癫痫发作频率降低≥50%，分别有36.6%和30.9%的患者实现无发作。2年时，73.2%的患者报告其病情较基线“极大改善”或“明显改善”；37.5%的患者报告了与治疗相关的不良药物反应。

意义：对于药物抵抗性癫痫患者，司妥赛治疗可实现长期的高无发作率，并显著减少合并使用的抗癫痫药物，同时还表现出良好的耐受性和较高的患者满意度。

### 第二部分 AI 大师评价

该研究通过一项西班牙的真实世界回顾性研究，评估了司妥赛（cenobamate）作为辅助疗法在药物抵抗性癫痫患者中的长期（长达两年）疗效与安全性。其核心价值在于不仅证实了司妥赛能高效控制癫痫发作（实现高比例的无发作率），更关键地揭示了它能显著减少合并使用的抗癫痫药物数量与剂量。这一发现对于临床实践意义重大，意味着司妥赛有望简化复杂的治疗方案，降低多重用药带来的负担与风险。尽管研究为单中心回顾性设计，但其长期的随访数据为司妥赛在真实临床环境下的应用提供了强有力的证据。

---

速递结束，祝您工作愉快！